8-K: Entera Bio Announces Q1 2025 Financial Results and Business Updates, Highlighting Progress in Oral Peptide Therapies

Entera Bio reported its Q1 2025 financial results and business updates, showcasing advancements in its oral peptide and protein replacement therapies, including EB613 for osteoporosis and a collaboration with OPKO Health.

Summary

• Entera Bio announced its Q1 2025 financial results, reporting a net loss of $2.6 million, or $0.06 per ordinary share.
• Research and development expenses were $1.1 million, up from $0.7 million in the same period last year.
• General and administrative expenses increased slightly to $1.4 million.
• The company's cash and cash equivalents stood at $20.6 million as of March 31, 2025, expected to fund operations through mid Q3 2026.
• Entera Bio is progressing with its EB613 program, an oral anabolic tablet treatment for osteoporosis, and plans to initiate a Phase 1 study for its Next Gen EB613 tablet candidate in H2 2025.
• The company has also partnered with OPKO Health to co-develop Oral OPK-88006, a dual-acting GLP1/Glucagon single tablet for metabolic diseases, retaining a 40% stake in the economics.
• Entera Bio is judiciously strengthening its core team with important appointments including Ms. Leslie Gautam, as Chief Business Officer and Ms. Cherin Smith as Head of Clinical Operations.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, it has made progress in its clinical programs, secured funding through a collaboration with OPKO Health, and strengthened its management team. The extension of the cash runway into late 2026 is also a positive sign.

Positives

• The company's cash runway extends into late 2026.
• EB613 showed positive mechanistic effects on bone compartments.
• The collaboration with OPKO Health provides funding and expertise for Oral OPK-88006 development.
• Entera Bio is progressing with its EB613 program, an oral anabolic tablet treatment for osteoporosis.
• The company has strengthened its core team with the addition of a new Chief Business Officer and Head of Clinical Operations.

Negatives

• The company reported a net loss of $2.6 million for the quarter ended March 31, 2025, compared to a net loss of $2.0 million for the same period in 2024.
• Operating expenses for the three Months ended March 31, 2025 were $2.6 million, as compared to $2.1 million for the three Months ended March 31, 2024.

Risks

• Changes in the interpretation of clinical data could impact the EB613 program.
• Unexpected changes in preclinical development and clinical trials could delay progress.
• The company's ability to obtain and maintain regulatory approvals for its product candidates is uncertain.
• Entera's reliance on third parties to conduct its clinical trials poses a risk.
• Entera's ability to continue as a going concern absent access to sources of liquidity is a risk.

Future Outlook

Entera Bio expects its cash to be sufficient to support operations through the middle of the third quarter of 2026 and plans to initiate a Phase 1 study for its Next Gen EB613 tablet candidate in H2 2025. The company also expects to file an Investigational New Drug application with the FDA later this year or early in 2026 for Oral OPK-88006.

Management Comments

• We continue to optimize and prepare to initiate our proposed pivotal program for EB613, the first and only oral anabolic bone building tablet treatment under clinical investigation in postmenopausal women with osteoporosis, said Miranda Toledano, Chief Executive Officer of Entera.
• We will be taking additional steps to ensure the continuity of clinical development for EB613, said Miranda Toledano, Chief Executive Officer of Entera.
• I'm honored to join Entera at such a pivotal moment for women's health... Im excited to help accelerate that mission, said Leslie Gautam, Chief Business Officer of Entera.

Industry Context

Entera Bio is operating in the competitive fields of osteoporosis, obesity, and short bowel syndrome treatments. The company is focusing on oral peptide therapies as an alternative to injectable treatments, which could address unmet needs and improve patient compliance. The potential FDA ruling on BMD as a surrogate for fracture risk is crucial for the company's EB613 program and the broader osteoporosis drug development landscape.

Comparison to Industry Standards

• The SABRE initiative's efforts to qualify BMD as a surrogate for fracture risk reduction are analogous to prior initiatives that qualified LDL cholesterol as a surrogate to cardiovascular outcomes and HBA1C as a surrogate to diabetes complications.
• EB613 comprises the first 34 N-terminal amino acid sequence of the human parathyroid hormone, PTH(1-34) or teriparatide, which is a validated standard of care and only available as a daily subcutaneous injection.
• Cherin Smith led the successful execution of 11 Phase 3 trials with BMD endpoints, including registrational Phase 3 programs for Orilissa, Myfembree, and Veozah, and has contributed to NDA submissions.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and progress in clinical programs may impact shareholder value.
• Employees: The company's growth and development activities may create new opportunities for employees.
• Patients: The development of oral peptide therapies could provide more convenient and effective treatment options for patients with osteoporosis, obesity, and short bowel syndrome.
• OPKO Health: The collaboration with OPKO Health will impact the development and commercialization of Oral OPK-88006 and other programs.

Next Steps

• Initiate a Phase 1 study for Next Gen EB613 tablet candidate in H2 2025.
• Submit an abstract on Next Gen EB613 to a major medical conference in 2025.
• File an Investigational New Drug application with the FDA later this year or early in 2026 for Oral OPK-88006.
• Submit abstracts to a major clinical conference with PK/PD of the single daily tablet of GLP-2 in late 2025.
• Prepare to initiate a Phase 3 registrational study for EB613 pursuant to the FDAs qualification of a quantitative BMD endpoint.

Key Dates

Keywords

Entera Bio, EB613, Osteoporosis, Oral Peptide, OPKO Health, GLP-1, GLP-2, Financial Results, Clinical Trials, Metabolic Diseases